Navigation Links
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remission and mucosal healing indications in adults living with UC.

UC is a chronic inflammatory bowel disease (IBD) of the colon.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.(1)  

"The results of this study are consistent with findings from the Active Ulcerative Colitis (ACT) trials, which evaluated REMICADE in the treatment of adults with ulcerative colitis," said Jeffrey Hyams, Head of the Division of Digestive Diseases and Nutrition at Connecticut Children's Medical Center and Professor of Pediatrics at University of Connecticut School of Medicine, and lead study investigator.  "UC can be a devastating disease, particularly for children and adolescents.  It is encouraging to see such promising results in a patient population that is in need of additional treatment options."

In December 2010, Centocor Ortho Biotech Inc. submitted a supplemental Biologics License Application (sBLA) to the FDA requesting the approval of REMICADE (infliximab) for the treatment of modera
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts og SHENZHEN ... Tech Solutions Co., LTD, (BGI Tech), et datterselskab ... lancering af en ny human whole exome-sekvenseringstjeneste baseret ... Complete Genomics, højt anset i branchen for at ... højfølsom registrering af alle typer varianter, blev købt ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... on August 21 and Roth Capital,s 2007 New York ... ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- a leading ... water, agricultural, environmental and,life science applications, announced today that its ...
... BioMaxx Systems Inc. (Other,OTC: BMXSF), is pleased ... with,Alcofuel Technologies Ltd., for the provision of the ... to the engagement,letter, Alcofuel Technologies has agreed, subject ... to design and manufacture a small,scale ethanol micro-refinery ...
... Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... product candidates for the treatment,of cancer and ... Food and,Drug Administration (FDA) has granted fast ... is currently being investigated in a,pivotal Phase ...
Cached Biology Technology:Strategic Diagnostics to Present at Two Upcoming Investor Conferences 2Strategic Diagnostics to Present at Two Upcoming Investor Conferences 3Strategic Diagnostics to Present at Two Upcoming Investor Conferences 4Strategic Diagnostics to Present at Two Upcoming Investor Conferences 5BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:7/22/2014)... emerging as a world-famous vacation spot with natural tourism resources, ... island. The Korea Institute of Geoscience and Mineral Resources (KIGAM) ... recent volcanic eruption was evident 5,000 years ago. That is ... lava spewed out of a volcano 5,000 years ago in ... one the whole peninsula. , The research team led by ...
(Date:7/22/2014)... is known about the the genus of planthopper known ... new one was recently discovered in the southern part ... Jaen. A description of it appears in the open-access ... ). , The new species, Conosimus baenai , ... for his contributions to the taxonomy of Iberian Hemiptera. ...
(Date:7/21/2014)... Their scruffy beards weren,t ironic, but there are reasons ... the Ice Age. , According to research from the ... liked living in Greater Cincinnati long before it was ... age. A study led by Brooke Crowley, an assistant ... enjoyed the area so much they likely were year-round ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3
... scientist from The Scripps Research Institute has identified a new ... formation. The molecule could become a target for the development ... as Hemophilia A. The findings, from a study by ... a recent edition of Journal of Biological Chemistry . ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
... - A Purdue University scientist has found genetic evidence of ... finding he believes could one day be used to help ... Salt, a professor of horticulture, noticed several years ago that ... tolerate higher levels of sodium had come from coastal areas. ...
Cached Biology News:Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2Plants can adapt genetically to survive harsh environments 2